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Abstract  
Introduction: The benefits of the use of antibiotics in the mass treatment for active trachoma and other diseases have been documented, but the 
secondary effects arising from such a programme have not been fully elucidated. The purpose of this study was to investigate the potential 
secondary benefits arising from the use of azithromycin in mass treatment of active trachoma in an economically challenged Kenyan nomadic 
community. Methods: Health information reports for January 2005 to December 2010 were reviewed to determine the annual trends of infectious 
diseases in the two districts, Narok and Transmara. The year 2007 was considered as the baseline for mass drug administration (MDA). Odds ratios 
(OR) were used to describe the association. Results: The mass distribution coverage in Narok was 83% in 2008, 74% in 2009 and 63% in 2010. 
The odds for malaria (OR = 1.13; 95% CI 1.12-1.14), diarrhoeal diseases (OR = 1.04; 95% CI 1.01-1.06), urinary tract infections (UTIs) (OR = 
1.21; 95% CI 1.17-1.26), intestinal worms (OR, 4.98; 95% CI 4.68-5.3), and respiratory diseases other than pneumonia (OR, 1.15; 95% CI 1.13-
1.16) were higher after three rounds of mass treatment, indicating a better outcome. Before the intervention, there was a reducing trend in the 
odds for respiratory diseases. In Transmara (control), there was an increase in odds for malaria, respiratory infections, UTIs and intestinal worms. 
The odds for diarrhoeal diseases, skin diseases and pneumonia decreased throughout the study period. Conclusion: Mass distribution of 
azithromycin may have contributed to the decrease in the prevalence of the respiratory infections in Narok District. 
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Introduction 
 
The mass administration of antibiotics has been used in the 
prevention and treatment of bacterial diseases. It has been 
recognized as a potentially vital and important public health strategy 
towards the control of neglected tropical diseases and other co-
infections in sub-Saharan Africa, whereby the provision of universal 
healthcare is still a major challenge. It has also been considered as 
a cost-effective method because of geographic overlaps of various 
diseases and high level of poverty in the region. Despite this, the 
secondary health benefits effects of such a programme have not 
been fully expounded, especially in developing countries whereby 
provision of universal healthcare is still a major challenge. The 
purpose of this study was to investigate the secondary benefits 
arising from the mass administration of azithromycin, an antibiotic in 
the mass treatment of active trachoma in an economically 
challenged Kenyan nomadic community. This was achieved by 
examining the trends of diseases two years before, and after the 
drug administration. The administration of azithromycin was part of 
the SAFE strategy (Surgery, Antibiotics, Facial and Environmental 
cleanliness) conducted in Narok district in Kenya from 2007 to 2010. 
The F&E components had not been fully implemented in the entire 
district at the time of this study. The findings were compared with 
those of neighbouring Transmara district, which is trachoma-
endemic but had no trachoma control project. 
  
Trachoma is still endemic in developing countries and is the 
common cause of infectious blindness. Most of the afflicted are poor 
people with low hygiene and inadequate access to clean water. 
They are therefore vulnerable to several other infections [1, 2]. As a 
strategy to eradicate trachoma, the World Health Organization 
(WHO) adopted the SAFE programme consisting of Surgery, 
Antibiotics for infectious trachoma, Facial cleanliness to reduce 
transmission and Environmental cleanliness to improve hygiene and 
sanitation. It recommends mass distribution of antibiotic in affected 
areas with prevalence of active trachoma of more than 10% in 
children aged 1 to 9 years in a district, or 5% for the community 
[3, 4] . 
  
Trachoma control programs in some of districts are currently on 
going in Kenya. The SAFE programme, implemented in Shampole, 
Kajiado district reported reduction in prevalence of active trachoma 
from 46% to 16% and the potentially blinding trachoma from 4.5% 
to 1.7% over a period of one year with low incidences of 
recurrences [5]. SAFE strategy programme in the greater Narok 
district began in 2008 and proceeded annually for three years, with 
the support from Operation Eyesight Universal (OEU). The 
prevalence of trachoma in Narok district is 30.5% [6]. Azithromycin 
is currently the antibiotic of choice administered in repeated annual 
community mass treatment for a period of three years [7]. It is 
administered as a single dose of 1 gm for adults whereas the 
children's dose is 20 mg/kg. Expectant mothers and children less 
than six months are put on tetracycline eye ointment [8]. The F&E 
activities involve preventive measures to reduce disease 
transmission which includes the provision of water, health 
promotion and education. The full benefits of the F&E activities 
generally take a longer period to be realized owing to the challenges 
of its implementation [9-11]. 
  
Previous studies have demonstrated that azithromycin markedly 
decreases the prevalence of ocular strains of Chlamydia 
trachomatis, the causative agent for trachoma [12, 13]. Whereas 
mass treatment has been shown to reduce the prevalence of 
trachoma, the potential secondary health benefits of such treatment 
have not been well documented. Previous studies regarding its 
impact on the prevalence of respiratory infections have been 
inconclusive. In a study among children in Ethiopia, the authors 
reported a decline in the overall mortality, perhaps due to 
respiratory infections, diarrhoea and malaria [14, 15]. An indirect 
protective effect against trachoma among untreated children 
residing in villages where most individuals have been treated, and 
decline in pneumococcal resistance has also been reported after 
mass treatment in Ethiopia [16, 17]. However, other authors in 
related studies concluded that it may lead to the emergence of 
resistant strains of Streptococcus pneumonia [18, 19]. The aim of 
this study therefore, was to investigate the potential secondary 
benefits arising from the mass treatment. 
  
  
Methods 
 
This community based operational research was conducted in the 
Narok County between August and November 2010. Permission to 
conduct the research was granted by the Institutional Research and 
Ethics Committee of Moi University. All the analyzed data were 
anonymized. Data on annual morbidity from January 2005 to 
December 2010 was obtained from Medical Officer of Health, Narok 
district. The data was collected using the standard Ministry of Health 
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reporting tools from all health facilities. All patients attended to in 
these facilities were included in the study. Monthly records of the 
incidences of all new diseases and their frequencies in each facility 
were recorded. The monthly morbidity reports were then compiled 
and an annual summary determined. The prevalence of the seven 
most common infectious diseases was then assessed. We took 2007 
as the baseline, since the implementation of the SAFE strategy 
commenced in 2008, and investigated the trends of the diseases 
two years before (2005 - 2006), and three years after (2008 - 
2010). The Narok data for the period 2005 to 2007 (baseline) was 
used to establish the magnitude and "natural tends" 
(annual/monthly) of prevalent infectious diseases prior to MDA. 
Additionally, the 2007 to 2010 trend was compared with that for 
Transmara to determine whether the treatment was beneficial or 
not. At the time of the study, F&E activities in Narok were at its 
inception and had not achieved a wider coverage. In both Narok 
and Transmara districts, there were F&E activities being provided 
under the National Community Health Strategy programme. It was 
therefore assumed that any change in disease patterns was 
attributable to the MDA. We also reported the trends in the 
diseases. 
  
Statistical analysis 
  
The number of patients treated in each month was aggregated to 
the totals for the year. The base year analysis was set to 2007, 
which was the year used to compute the test statistics. Analysis was 
performed using STATA software version.10 (STATACorp, College 
Station, Texas 7784) in order to compare the proportions of the 
various diseases before and after the intervention. Chi-square test 
was used to determine the association between respective years 
and the base year (2007) in respect of the various diseases. Odds 
ratios and significance of the chi-square test were used as indicators 
of prevalence. For years after 2007, an OR>1 implied that the 
intervention had a beneficial effect, meaning that the proportion of 
cases in the following respective year was lower, or a decline in 
prevalence following the treatment/intervention. An OR<1 implied 
that the intervention had no impact in the successive year (the 
proportion of the case in that year were significantly higher than the 
base year). The converse was true for the years before 2007. An 
(OR>1) implied that the prevalence before the intervention was 
lower, that is the proportion of cases in 2007 was significantly 
higher than those in the prior year. An OR<1 implied that the 
proportion was higher before the intervention. 
  
Results 
 
The mass distribution coverage in Narok district decreased over the 
study period; 83% in 2008, 74% in 2009 and 63% in 2010. 
Respiratory diseases and malaria were the most prevalent diseases. 
The prevalence of pneumonia was between 5% and 7% while that 
of the other diseases of the respiratory system ranged from 30% to 
34%. Malaria had a prevalence of between 22% and 29% over the 
study period. The prevalence of the other infections recorded is as 
in Table 1. Apart from the diarrhoeal diseases, there was a general 
decline in all the other recorded infectious diseases after the third 
year from the baseline, despite the decreased percentage coverage 
over the period (Table 1, Figure 1). Respiratory diseases were 
significantly more prevalent in the years prior to the intervention 
compared to the period after the use of antibiotics. The proportions 
of patients with malaria decreased throughout the study period. The 
prevalence for both diseases rose proportionately with the 
corresponding decrease in coverage from the second to the third 
round (malaria 25% vs. 22%, respiratory diseases 31% vs. 30%). 
There was a statistically significant increase in proportion of 
pneumonia during this period (Figure 1).There were statistically 
significant changes in the odds for all diseases except skin diseases 
three rounds after the intervention. The odds for malaria 
(68580(27%) vs. 63900(25%); OR, 1.13; 95% CI 1.12-1.14), 
diarrhoeal diseases (21253(8%) vs. 21010(8%); OR, 1.04; 95% CI 
1.01-1.06), UTIs (6646(3%) vs. 5609(2%); OR, 1.21; 95% CI 1.17-
1.26), intestinal worms (5834(2%) vs. 1218(0%); OR, 4.98; 95% CI 
4.68-5.3), and respiratory diseases other than pneumonia (87163 
(34%) vs. 81101 (31%); OR, 1.15; 95% CI 1.13-1.16) were higher 
after three rounds of mass treatment, indicating a better outcome 
or a reduction in the prevalence of the diseases. The odds for 
pneumonia decreased (15742(6%) vs. 17001(7%); OR, 0.94; 95% 
CI 0.92-0.96), although the odds were higher after the second 
round 15742(6%) vs. 9750(5%); 1.32(1.28-1.35) before rising after 
the third round. There was no significant change in odds for the skin 
diseases. 
  
In Transmara (control), there was an increase in the odds for 
malaria, respiratory infections, UTIs and intestinal worms. The odds 
for diarrhoeal diseases, skin diseases and pneumonia decreased but 
significantly in this case, the odds decreased throughout the period 
(Table 3, Figure 2). There were no records for Transmara for the 
2005 and 2006 years. The crossing of the residents from Transmara 
to Narok district may have affected the results. The number of 
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patients in the study was quite high and therefore any small 
percentage change translated in statistically significant changes 
(Table 1, Table 2). There were no records for Transmara for the 
2005 and 2006 years. The crossing of the residents from Transmara 
to Narok district may have affected the results. The number of 
patients in the study was quite high and therefore any small 
percentage change translated in statistically significant changes 
(Table 1, Table 2). There was a change from manual to electronic 
data recording in 2008 which could have resulted in the loss of 
some data. This may explain the comparatively low numbers 
recorded in 2008. 
  
  
Discussion 
 
The provision of basic healthcare is still a major challenge in 
developing countries and respiratory diseases, malaria and 
diarrhoea have been identified as the leading death of children in 
developing countries [20-22]. Mass drug administration and 
integrated control has now been recognized as a vital and important 
public health solution towards the control of neglected tropical 
diseases and other co-infections in sub-Saharan Africa [23-25]. 
Previous studies have demonstrated that this strategy is a cost-
effective method because of the geographic overlaps of the various 
diseases and the high level of poverty in the region. It has also been 
shown to be safe and efficacious [26, 27]. Our study was set in a 
community that is poor and of low hygiene, and therefore quite 
vulnerable to several diseases due to inaccessibility of water and 
sanitation among other problems. The provision of health services is 
also a major challenge owing to their pastoralist and nomadic way 
of life. The purpose of our study was to investigate the potential 
benefits arising from the mass administration of azithromycin in 
resource-limiting settings. We utilized the data from an existing 
programme for the control of infectious trachoma to determine the 
potential secondary effects resulting from mass administration of 
azithromycin. Our results suggest that the mass administration of 
azithromycin may have some secondary beneficial effects. 
  
Antibiotic prophylaxis has been used to reduce the incidences of 
streptococcal infections, and azithromycin has been shown to 
control pneumonia epidemics in army recruits [28-31] . In addition, 
azithromycin and chloroquine combination has been shown to be 
effective in the prevention and treatment of both malaria and 
sexually transmitted diseases in pregnancy [32, 33]. The collateral 
benefits of antibiotic prophylaxis in Africa have not been well 
documented. Most of the reported studies relate to the use of 
azithromycin in trachoma control programs. The authors in previous 
studies conducted in rural Ethiopian villages concluded that the 
mass administration of azithromycin led to a decline in the 
respiratory infections and pneumococcal resistance. In addition 
there was a reported decrease in the prevalence of malaria and 
diarrhoea [14, 17]. In a separate study conducted in Gambia, the 
authors concluded that it reduced the childhood morbidity [34]. A 
recent study, also conducted in Ethiopia concluded that mass 
administration of azithromycin in a trachoma control programme 
reduced all-cause and infections childhood mortality [15]. We 
observed a decrease in the prevalence of respiratory infections, 
including pneumonia upon intervention with azithromycin. 
  
Malaria is only second to HIV/AIDS as a cause of death in Sub-
Saharan Africa, and is the leading cause of death in children below 
the age of five whereby it is responsible for over 800,000 million 
deaths each year [22, 35-37]. From our studies, there was a general 
decline in the proportion of patients with malaria throughout the 
study period with a sharp decline two years after the intervention. 
This could in part be attributed to an ongoing parallel programme in 
the whole region (Narok and Transmara included), which involved 
the distribution of mosquito of nets. However it should be noted 
that azithromycin has been demonstrated to posses the potential for 
prophylaxis and treatment of malaria alone, or in combination of 
other therapies [38-41]. Indeed it has been tried in Africa, and in a 
trial in Western Kenya, the authors concluded that it was efficacious 
for prophylaxis against malaria [42, 43]. Studies conducted in Asia 
have also demonstrated that azithromycin is quite tolerable in the 
treatment of malaria [44]. 
  
The mass distribution coverage of the population in Narok district 
was 83% in 2008, 74% in 2009 and 63% in 2010 respectively [6]. 
Our findings indicated an increase in the incidences of diarrhoeal 
diseases after the second year. These results are inconsistent with 
earlier findings conducted in Nepal, Ethiopia and Gambia 
respectively [14, 18, 34]. This could be attributed to several other 
factors including hygiene and sanitation, as well as the weather 
patterns. There were significant decreases in the diseases of the 
skin, urinary tract infections and reported cases of intestinal worms 
after the second year. Azithromycin has been shown to reduce the 
incidents of STIs in previous studies conducted on commercial sex 
workers in Philippines [45]. 
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These findings suggest that the mass distribution appears to reduce 
incidence of the infectious diseases. Antibiotic prophylaxis is 
justifiable in the management of trachoma and several other 
diseases. However careful considerations have to be made with 
regards to the benefits of mass use of antibiotics. The literature is 
awash with specific dangers of non-specific mass use of antibiotics 
such as development of resistance and adverse drug effects among 
others. Continuous surveillance is important to assess the actual 
benefits of such a programme. But it is also important to consider 
the cost-benefit ratio especially in such settings where the residents 
have little access to health services owing to poverty, illiteracy and 
their way of life. Further studies should be conducted to ascertain 
the adverse and beneficial effects of such approaches in the 
development of public health policies in such settings. 
  
There are several limitations in our study. We did not obtain data on 
the demographics of the patients and were therefore unable to 
determine the extent any confounding factors to the results. Some 
patients may not have been seen after the administration of 
azithromycin. We also made the assumption that the diagnosis was 
correct. Most of the previous studies have been undertaken in 
children less than five years, whereby antibiotic administration may 
make better impact owing to the less developed immunities. We 
could only obtain records for the years 2008-2010. There are also 
several other confounders which include the weather, which may 
have affected the disease patterns of diarrhoea, pneumonia and 
malaria. The migration of the residents in response to the weather 
changes and the difficulties in measuring the effects of F&E could 
have also affected our results. 
  
  
Conclusion 
 
Our findings demonstrate that the mass distribution of azithromycin 
may have contributed to the decrease in the prevalence of the 
respiratory infections in Narok District. 
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Table 1: proportion of patients with various illnesses at the baseline and after mass administration of azithromycin in Narok District 
 
Number of patients (%) 
Year n1 
(2007/08) 
2007* 
n2 (%) 
2008 
n2 (%) 
2008 vs. 2007 n1 
(07/09) 
2009  
n2 (%) 
2009 vs. 2007 n1 
(07/10) 
2010 2010 vs. 2007 
Condition 
or 
symptom 
Total no. of 
patients 
n2 = 
255132 
124472 
(%) 
OR  (95% CI) Total no. 
of 
patients 
n2 
=204792 
OR (95% CI) Total no. 
of 
patients 
n2 = 
260359 
OR (95% CI) 
Pneumonia 23310 15742(6) 7568(6) 1.02(0.99-1.05) 25492 9750 (5) 1.32(1.28-1.35) 32743 17001(7) 0.94(0.92-0.96) 
Other 
diseases of 
the 
respiratory 
system 
133041 87163(34) 45878(37) 0.89(0.88-0.90) 148123 60960(30) 1.22(1.21-1.24) 168264 81101(31) 1.15(1.13-1.16) 
Diarrhoeal 
diseases 
31759 21253(8) 10506(8) 0.99(0.96-1.01) 41349 20096(10) 0.84(0.82-0.85) 42263 21010(8) 1.04(1.01-1.06) 
Malaria 101156 68580(27) 32576(26) 1.04(1.02-1.05) 112965 44385(22) 1.33 (1.31-1.35) 132480 63900(25) 1.13(1.12-1.14) 
Intestinal 
worms 
8287 5834(2) 2903(2) 0.98(0.94-1.03) 7141 1307 (1) 3.64(3.43-3.87) 7052 1218(0) 4.98(4.68-5.3) 
Disease of 
the skin 
(including 
ulcers) 
23371 15519(6) 7852(6) 0.96(0.94-0.99) 23233 7714 (5) 1.65(1.61-1.70) 31513 15994(6) 0.99(0.97-1.01) 
Urinary 
tract 
infections 
9663 6646(3) 3017(2) 1.08(1.03-1.12) 9371 2725 (1) 1.98(1.90-2.07) 12255 5609(2) 1.21(1.17-1.26) 
n1 = Total number of patients with a certain condition for the year and the baseline (2007*) e.g. n1 for pneumonia in 2007/2008 = 23310 (that is the sum of 15742 and 7568) 
n2 = Total number of patients with all conditions for the respective year, e.g. the number of patients with pneumonia in 2007 = 15742 which is 6% of n2 
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Table 2: proportion of patients with various illnesses before the mass administration of azithromycin in Narok District 
 
Number of patients (%) 
Year n1 (05/07) 2005 
 n2 (%) 
2005 vs. 2007 n1 (06/07) 2006 
 n2 (%) 
2006 vs. 2007 2007* 
 n2 (%) 
Condition or symptom Total no. of 
patients 
n2 = 
208221 
OR  (95% CI) Total no. of 
patients 
n2= 
224954 
OR (95% CI) n2 = 
255132 
Pneumonia 29665 13923(7) 0.92 (0.9-0.94) 27894 12152(5) 1.15 (1.02-1.07) 15742(6) 
Other diseases of the 
respiratory system 
155484 68321(33) 1.06 (1.05-1.08) 158846 71683(32) 1.11 (1.1-1.12) 87163(34) 
Diarrhoeal diseases 39933 18680(9) 0.92 (0.9-0.84) 43313 22060(10) 0.84 (0.82 -0.85) 21253(8) 
Malaria 128511 59931(29) 0.91(0.9-0.92) 130482 61902(28) 0.97 (0.96-0 .98) 68580(27) 
Intestinal worms 11597 5763(3) 0.82(0.79-0.85) 10520 4686(2) 1.10 (1.06-1.14) 5834(2) 
Disease of the skin 
(including ulcers) 
31753 16234(8) 0.77 (0.75-0.78) 30479 14690(7) 0.93 (0.91-0.95) 15519(6) 
Urinary tract infections 13077 6431(3) 0.84 (0.81-0.87) 13027 6381(3) 0.92 (0.88-0.95) 6646(3) 
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Table 3: transmara, Proportion of patients with various illnesses at the baseline and one and two years after the mass administration of azithromycin in Transmara District 
  Number of patients (%) 
 Year n1  (07/08) 2007*  
n2 (%) 
2008  
n2 (%) 
2008 vs. 
2007 
n1 
(07/09) 
2009  
n2 (%) 
2009 vs. 
2007 
n1 
(07/010) 
2010  
n2 (%) 
2010 vs. 
2007 
Condition or 
symptom 
Total no. of 
patients 
n2 = 156839 n = 
141628 
OR  (95% 
CI) 
Total 
no. of 
patients 
n2= 
199599 
OR  (95% 
CI) 
Total no. 
of 
patients 
n2= 
233313 
OR  
(95% 
CI) 
Pneumonia 
12683 6170(4) 6513(5) 
0.85(0.82-
0.88) 
16408 10238(5) 
0.76(0.73-
0.78 
16437 10267(4) 
0.89(0.86-
0.92) 
Other diseases 
of the respiratory 
system 
90853 48898(31) 41955(30) 
1.08(1.06-
1.09) 
104526 55628(28) 
1.17(1.16-
1.19) 
118442 69544(30) 
1.07(1.05-
1.08) 
Diarrhoeal 
diseases 
21772 10789(7) 10983(8) 
0.88(0.85-
0.9) 
27022 16233(8) 
0.83(0.81-
0.86) 
28518 17729(8) 
0.9(0.88-
0.92) 
Malaria 
103311 56856(36) 46455(33) 
1.17(1.15-
1.18) 
59246 2390(1) 
46.92(45.01-
48.92) 
129932 73076(31) 
1.25(1.23-
1.26) 
Intestinal worms 
10718 5614(4) 5104(4) 
0.99(0.96-
1.03) 
10300 4686(2) 
1.54(1.48-
1.61) 
8347 2733(1) 
3.13(2.99-
3.28) 
Disease of the 
skin (including 
ulcers) 
27385 12970(8) 14415(10) 
0.80(0.78-
0.82) 
32630 19660(10) 
0.83(0.81-
0.84) 
39494 26524(11) 
0.7(0.69-
0.72) 
Urinary tract 
infections 
4432 2488(2) 1944(1) 
1.16(1.09-
1.23) 
4562 2074(1) 
1.54(1.45-
1.63) 
5372 2884(1) 
1.29(1.22-
1.36) 
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Figure 1: comparison of the proportions of the patients with various illnesses over a period of five years in 
Narok district 
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Figure 2: comparison of the proportions of the patients with various illnesses between 2007 and 2010 in 
Transmara district 
 
